Zheng Quan Shi Bao Wang·2025-12-18 13:32Core Viewpoint - Guangzhou Pharmaceutical, a subsidiary of Baiyunshan, has successfully acquired 100% equity of Zhejiang Pharmaceutical Industry Co., Ltd. from Haizheng Pharmaceutical for 500 million yuan, marking a strategic move to enhance its market presence in East China [1][2]. Group 1: Acquisition Details - The acquisition process began with a public transfer, where Guangzhou Pharmaceutical won the bid at a price of 500 million yuan on December 10, 2023, and paid a deposit of 86 million yuan [1]. - Zhejiang Pharmaceutical is a leading pharmaceutical distribution company in Zhejiang, with a distribution network covering over 99% of public hospitals in the province [1]. Group 2: Strategic Importance - This acquisition is seen as a significant step for Guangzhou Pharmaceutical to strengthen its presence in the East China market, which is crucial for pharmaceutical distribution due to its high population density and strong medical consumption capacity [2]. - The deal is expected to create synergies between Guangzhou Pharmaceutical and Zhejiang Pharmaceutical, enhancing resource sharing, business collaboration, and channel integration [3]. Group 3: Future Prospects - Post-acquisition, Guangzhou Pharmaceutical aims to leverage Zhejiang Pharmaceutical's established distribution network to accelerate the implementation of innovative business models such as SPD and pharmaceutical e-commerce in the Yangtze River Delta region [3]. - The acquisition aligns with Baiyunshan's broader strategy of capital operations, which includes recent acquisitions in various sectors such as traditional Chinese medicine and diagnostics, showcasing a clear trend of upstream and downstream integration [4].